Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$56.33 USD

56.33
1,338,701

+0.22 (0.39%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $56.32 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Alnylam & Medison Partner to Market RNAi Products in Israel

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.

Merck's Partner Gets FDA Nod for Herceptin Biosimilar

Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.

Top Ranked Income Stocks to Buy for January 21st

Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 21st:

Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

Top Ranked Income Stocks to Buy for January 18th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 18th

Regeneron (REGN) Sails Steady on Label Expansion of Drugs

Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

Regeneron, Sanofi Restructure Immuno-Oncology Collaboration

Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.

Emergent (EBS) Files Application for Emergency Use of NuThrax

Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine

Sanofi (SNY) gains an FDA approval for its pediatric hexavalent combination vaccine, Vaxelis.

The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy

The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy

Kalyan Nandy headshot

Top Analyst Reports: Apple, Microsoft, Mastercard & More

Today's Research Daily features updated research reports on 16 major stocks including Apple Inc. (AAPL), Microsoft Corporation (MSFT) and Mastercard Inc. (MA).

Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus

Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.

Kinjel Shah headshot

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Here are five stocks that are attractive and most likely to be takeout targets in 2019.

Kinjel Shah headshot

4 Big Pharma Stocks to Add to Your Portfolio in December

The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.

Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs

FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs

The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources

The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources

Glaxo Seeks Label Expansion of Nucala in Pediatric Patients

Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.

Mark Vickery headshot

Top Stock Reports for Sanofi, Novo Nordisk & NVIDIA

Today's Research Daily features new research reports on 16 major stocks, including Sanofi (SNY), Novo Nordisk (NVO) and NVIDIA (NVDA).

Alphabet Halts Glucose Lens Work to Focus on Other Projects

Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.

Regeneron (REGN) Rides on Eylea and Dupixent's Performance

Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.

Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges

With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.

Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3

Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.

Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss

Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.